Alpha Talon Investment Research

Alpha Talon Investment Research

Home
Notes
Power, Policy & Markets
Guides to Investing
Letters and Reflection
ATIR Portfolios
Asia Market
Industry Analysis
Good Quality High Dividend
Deep Value
IT
BioPharma Healthcare
Special Situation
M&A
Short Thesis
Archive
Newsletters
Leaderboard
About

BioPharma HealthCare

Grace Therapeutics, Inc. (GRCE): When Execution, Not Biology, Drives Value
A regulatory event thesis on IV nimodipine, ICU economics, and approval-then-optionality in aneurysmal subarachnoid hemorrhage
 • AT Investment Research
Alpha Talon Investment Research Analysis of the 44th Annual J.P.Morgan Healthcare Conference
The Companies We Own and What Their Presentations Actually Mean
 • AT Investment Research
HOPE-3 Under the Microscope: Data, Framing, and Regulatory Reality
Why "Statistically Positive Data", Procedural FDA Alignment, and Approval Risk Remain Fundamentally Misaligned
 • AT Investment Research
Milestone Pharmaceuticals (NASDAQ MIST): From Regulatory Success to Commercial Proof
CARDAMYST is approved and clinically validated. The remaining question is whether disciplined execution, payer alignment, and physician adoption can…
 • AT Investment Research
Viking Therapeutics (NASDAQ: VKTX): The Last Independent Metabolic Challenger
From Clinical Contender to Commercial Platform or a Multi-Billion-Dollar Takeout
 • AT Investment Research, The M&A Hunter, and Biotech Distilled
Novo Nordisk: From Insulin Giant to Global Metabolic Infrastructure
How the World’s Most Valuable Pharma Company Is Being Forced Into Its Hardest Strategic Transition Yet, And it Might be a Blessing for Patient Investors
 • AT Investment Research
Capricor Therapeutics (CAPR): HOPE-3 Isn’t the Turnaround the Market Priced It To Be
Why today’s “positive” data doesn’t change the regulatory math, and why my previous short selling thesis will hold
 • AT Investment Research
Pfizer Inc. (NYSE: PFE): From Blockbusters to Chornic-Care Infrastructure Provider
The market still values Pfizer like a fading COVID beneficiary; its real upside lies in industrializing total chronic healthcare the way it…
 • AT Investment Research
The $376 Question: What Comes After BRUKINSA and TEVIMBRA?
ONC deserves its premium, but it must still earn its next one. Only ADC impact, resistance-proof BTK strategy, or combo superiority unlocks true…
 • AT Investment Research
From Pipeline to Platform: Viking Therapeutics's (NASDAQ: VKTX) Metabolic Inflection Point
A Phase 3-ready disruptor with billion-dollar optionality and one of the cleanest balance sheets in biotech.
 • AT Investment Research
How Xeris Biopharma Broke the Small-Cap Curse
A small-cap biotech evolves into a self-funded specialty-pharma platform — with XP-8121 as the catalyst that could double revenue by 2030.
 • AT Investment Research and Rudy Does Research
Sarepta Therapeutics (NASDAQ:SRPT): From Hype to Hard Reality — A Binary Bet on Survival, Not Sympathy
ESSENCE broke the story, not the balance sheet. $865M cash, $2B sales, $400M cuts — Sarepta trades below liquidation as FDA holds its fate
 • AT Investment Research
© 2026 Alpha Talon Investment Research Limited · Privacy ∙ Terms ∙ Collection notice
Start your SubstackGet the app
Substack is the home for great culture